Haematologic outcomes and associated clinical characteristics among patients receiving Olaparib therapy in the UAE: a retrospective chart review by Lina Wahba, Said Nabil, Saba Kendakji, Mariam Ibrahim, Sham ZainAlAbdin, Salahdein Aburuz, Amal Akour

Subjects: “…Olaparib…”
Get full text

TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC by Xiao-Mei Tang, Min-Min Shi, Jia-Cheng Wang, Yi-Jin Gu, Yu-Ting Dai, Qin-Xin Yang, Jia Liu, Ling-Jie Ren, Xin-Yun Liu, Chun Yang, Fang-Fang Ma, Ji-Bing Liu, Hong Yu, Da Fu, Yun-Feng Wang

Subjects: Get full text

Olaparib induced aplastic anemia in a patient with castrate resistant prostate cancer: A case report by Elrazi A Ali, Monika Jain, Akriti Pokhrel, Unni Mooppan, Jen chin Wang

Subjects: Get full text

Cost-effectiveness analysis of durvalumab with chemotherapy and maintenance durvalumab with or without olaparib for advanced endometrial cancer by Jiahao Zhang, Jianying Lei, Caicong You, Wu Fu, Bin Zheng, Hongfu Cai, Maobai Liu, Na Li

Subjects: Get full text

Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib by Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, Karen Cadoo, Fiona Simpkins, Carol Aghajanian, Alexandra Leary, Andrés Poveda, Stephanie Lheureux, Eric Pujade-Lauraine, Benoit You, Jonathan Ledermann, Ursula Matulonis, Charlie Gourley, Kirsten M. Timms, Zhongwu Lai, Darren R. Hodgson, Cathy E. Elks, Simon Dearden, Coumaran Egile, Pierre Lao-Sirieix, Elizabeth A. Harrington, Jessica S. Brown

Subjects: Get full text

Pharmacokinetic Interaction Between Olaparib and Regorafenib in an Animal Model by Danuta Szkutnik-Fiedler, Agnieszka Karbownik, Filip Otto, Julia Maciejewska, Alicja Kuźnik, Tomasz Grabowski, Anna Wolc, Edmund Grześkowiak, Joanna Stanisławiak-Rudowicz, Edyta Szałek

Subjects: Get full text

Evaluation of Olaparib Tablet Safety and Pharmacokinetics in Healthy Chinese Male Subjects by Dong R, Chen J, Guo N, Yang Y, Wu J, Wang X, Song Y, Zhang X

Subjects: “…olaparib…”
Get full text

Real-world prevalence, treatment and survival of “high risk” early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Dat... by Sylvain Ladoire, Ariane Mamguem Kamga, Loick Galland, Isabelle Desmoulins, Didier Mayeur, Courèche Kaderbhai, Silvia Mihaelia Ilie, Audrey Hennequin, Clementine Jankowski, Juliette Albuisson, Sophie Nambot, Charles Coutant, Laurent Arnould, Manon Reda, Caroline Truntzer, Sandrine Dabakuyo

Subjects: Get full text

NLRP4 drives olaparib resistance in pancreatic cancer by Mingming Xiao, Xianjun Yu, Si Shi

Subjects: “…Olaparib…”
Get full text

Stem Cell Transplantation for Ovarian Cancer Patient with Associated Myelodysplasia After Maintenance Therapy with Olaparib: A Case Report by Linn Z, Gu Z, Wang L, Cai S

Subjects: Get full text

PARylation of HMGA1 desensitizes esophageal squamous cell carcinoma to olaparib by Xin‐Yuan Lei, Kai‐Yue He, Qiu‐Tong Li, Lei Zhang, Dan‐Hui Wu, Jing‐Yu Yang, Jin‐Rong Guo, Meng‐Jie Liu, Zi‐Long Zhao, Jun‐Qi Li, Huai Liu, Yuan Zhao, Yu‐Jia Li, Qian‐Hui Sun, Chen‐Guang Wu, Yun‐Fan Wang, Geng‐Sheng Cao, Gang Wang, Yong‐Ping Jian, Zhi‐Xiang Xu

Subjects: Get full text

Olaparib enhancing radiosensitization and anti-metastatic effect of oral cancer by targeting IL-17A signal by Chih-Chia Yu, Hon-Yi Lin, Michael W.Y. Chan, Shu-Fen Wu, Wen-Yen Chiou, Moon-Sing Lee, Chen-Lin Chi, Ru-Inn Lin, Feng-Chun Hsu, Hsuan-Ju Yang, Liang-Cheng Chen, Chia-Hui Chew, Shih-Kai Hung

Subjects: “…Olaparib…”
Get full text

Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma by Thao D. Pham, Jeffrey H. Becker, Anastasia E. Metropulos, Nida Mubin, Christina Spaulding, David J. Bentrem, Hidayatullah G. Munshi

Subjects: Get full text

Thioparib inhibits homologous recombination repair, activates the type I IFN response, and overcomes olaparib resistance by Li‐Min Wang, Pingyuan Wang, Xiao‐Min Chen, Hui Yang, Shan‐Shan Song, Zilan Song, Li Jia, Hua‐Dong Chen, Xu‐Bin Bao, Ne Guo, Xia‐Juan Huan, Yong Xi, Yan‐Yan Shen, Xin‐Ying Yang, Yi Su, Yi‐Ming Sun, Ying‐Lei Gao, Yi Chen, Jian Ding, Jing‐Yu Lang, Ze‐Hong Miao, Ao Zhang, Jin‐Xue He

Subjects: Get full text

Inhibiting ADAM17 enhances the efficacy of olaparib in ovarian cancer spheroids by Christoph Rogmans, Jan Dittrich, Emily Hamm, Jörg Paul Weimer, David Holthaus, Norbert Arnold, Inken Flörkemeier, Nicolai Maass, Peer Jansen, Astrid Dempfle, Dirk O. Bauerschlag, Nina Hedemann

Subjects: Get full text

Enhancing Effects of Olaparib by Alpha- and Beta-Emitting Radionuclides, X-Rays, and Ultraviolet A Light in Combination with Ortho-IodoHoechst in a Prostate Cancer Cell Model by Andrea C. Luna Mass, Roswitha Runge, Kerstin Wetzig, Lisa Huebinger, Claudia Brogsitter, Joerg Kotzerke

Subjects: Get full text

Olaparib monotherapy in advanced triple-negative breast cancer patients with homologous recombination deficiency and without germline mutations in BRCA1/2: The NOBROLA phase 2 stud... by Alfonso Cortés, Elena López-Miranda, Adela Fernández-Ortega, Vicente Carañana, Sonia Servitja, Ander Urruticoechea, Laura Lema-Roso, Antonia Márquez, Alexandros Lazaris, Daniel Alcalá-López, Leonardo Mina, Petra Gener, Jose Rodríguez-Morató, Gabriele Antonarelli, Antonio Llombart-Cussac, José Pérez-García, Javier Cortés

Subjects: Get full text

Economic impact of olaparib on maintenance treatment of patients with BRCA-mutation positive, platinum-sensitive relapsing high-grade serous epithelial ovarian cancer in Spain by Luis Cordero Puentes, Carlota Moya de Alarcón, David Carcedo, Jordi Ginés Rubió, Maria del Carmen Garcías de España, Laura Delgado-Ortega

Subjects: “…Olaparib;…”
Get full text